ASCUS With Negative HPV: When to Repeat Pap?

If your Pap smear came back as ASCUS but your HPV test was negative, the current guideline from the American Society for Colposcopy and Cervical Pathology (ASCCP) is to return for your next screening in three years, not sooner. That recommendation rests on strong data showing the five-year risk of serious cervical disease after this result combination is very low, roughly comparable to the risk after a normal Pap. But “very low” is not the same as zero, and the three-year timeline has some nuances worth understanding.

What ASCUS Actually Means on a Pap Result

ASCUS stands for “atypical squamous cells of undetermined significance.” In plain terms, the lab saw some cells that looked a little off but not clearly abnormal. It is the mildest and most common abnormal Pap finding, showing up in roughly five percent of all Pap smears. It sits in a gray zone: the cells are not normal, but they are not definitively precancerous either. The appearance can be caused by inflammation, low estrogen, a recent infection, or just the way a sample was collected. Because ASCUS is ambiguous by definition, the HPV test result that accompanies it matters enormously. A positive HPV test turns ASCUS into a finding that deserves closer evaluation, while a negative HPV test is strongly reassuring.

Why a Negative HPV Test Changes Everything

High-risk HPV is the necessary ingredient for nearly all cervical cancers. Without it, the slightly irregular cells that triggered the ASCUS call are overwhelmingly benign. In a study tracking over 1,500 women with HPV-negative ASCUS, only about 1.4 percent went on to develop high-grade precancer or worse during follow-up, compared with over 15 percent of women whose ASCUS was paired with a positive HPV test.¹ That tenfold difference in risk is why the management paths split so dramatically depending on the HPV result.

Two large analyses have quantified the five-year risk more precisely. One found the five-year risk of high-grade precancer (CIN3 or worse) after HPV-negative ASCUS was about 0.43 percent, and the risk of actual cervical cancer was 0.05 percent.² A second study put the five-year CIN3-or-worse risk at 0.48 percent and the cancer risk at 0.043 percent.³ Both studies found these numbers were close to the risk after a straightforwardly negative Pap. In practical terms, your risk of developing serious cervical disease is in the neighborhood of one in two hundred over five years, which is why guidelines do not call for aggressive follow-up.

The Three-Year Return Interval and Where It Comes From

The 2019 ASCCP risk-based management guidelines introduced a framework built on estimated CIN3-or-worse risk rather than rigid algorithms tied to specific Pap result categories. Under this framework, any screening result that puts a patient’s estimated five-year CIN3-or-worse risk below a certain threshold calls for routine-interval surveillance rather than immediate action. HPV-negative ASCUS falls comfortably in this low-risk zone, with an estimated five-year CIN3-or-worse risk of about 0.40 percent.⁴ That risk level triggers a recommendation to return in three years for repeat screening.

Three years might feel like a long wait after hearing the word “abnormal,” but the logic is sound. Cervical precancer develops slowly, typically over years to decades. The HPV-negative result tells you the primary driver of cervical cancer is not present right now. Even if HPV were acquired shortly after the test, it would take years for a new infection to progress to a dangerous lesion. Coming back in three years provides a generous safety margin while sparing you from unnecessary procedures and anxiety.

One subtlety worth noting: the three-year recommendation specifically applies when your screening history is unknown or unremarkable. If you have a history of treated precancer (like a prior LEEP or cone biopsy), the risk calculation changes, and your clinician may recommend a shorter follow-up interval regardless of the current HPV-negative ASCUS result.

HPV-Negative ASCUS Versus a Fully Normal Cotest

A common question is whether HPV-negative ASCUS carries any more risk than a completely clean bill of health, meaning both a normal Pap and a negative HPV test together. The answer is yes, slightly. The data show a statistically detectable gap. In one analysis, the five-year CIN3-or-worse risk after HPV-negative ASCUS was 0.43 percent versus 0.08 percent after a double-negative cotest.² The second large study found a similar pattern: 0.48 percent versus 0.11 percent.³

So HPV-negative ASCUS carries roughly four to five times the risk of a completely clean cotest. That sounds alarming until you remember the baseline: four to five times a very tiny number is still a very small number. Both risks are well below the threshold that would justify colposcopy or any immediate intervention. The practical difference is the follow-up interval: a double-negative cotest earns you five years before your next screen, while HPV-negative ASCUS brings you back in three. That two-year difference is the entire clinical consequence of the gap.

What Happens If ASCUS Keeps Showing Up

Some women get ASCUS results repeatedly. If ASCUS persists on your repeat Pap, even with a persistently negative HPV test, your clinician will need to consider whether something else is going on. One study that tracked women with persistent ASCUS found that among those sent for colposcopy after a second ASCUS result, about half had normal findings, but the other half had abnormalities on colposcopic examination. Directed biopsies in that group revealed low-grade lesions in about 21 percent and high-grade lesions in roughly 9 percent.⁵ This was an older study that did not stratify by HPV status, so the numbers likely overestimate what you would see in an HPV-negative population today. Still, persistent ASCUS is a reasonable trigger for a more thorough look, and most clinicians will discuss colposcopy if the pattern continues.

The reassurance of a negative HPV test weakens somewhat with repetition. If your cells keep looking atypical over multiple screening rounds despite negative HPV results, there is a small but real possibility that something other than HPV is causing the cellular changes, or that the HPV test missed a low-level infection. At that point, more investigation is warranted even if the numbers still suggest the odds are in your favor.

Postmenopausal Women and Atrophy-Related ASCUS

ASCUS results have a particular wrinkle in postmenopausal women. As estrogen levels decline, the vaginal and cervical lining thins out. This thinning, called atrophy, can cause cells to look mildly abnormal under the microscope, mimicking ASCUS. Research suggests that a short course of local estrogen therapy can help distinguish between atrophy masquerading as ASCUS and genuinely precancerous changes.⁶ After a few weeks of vaginal estrogen, the Pap is repeated. If the atypical cells disappear, the original finding was almost certainly due to hormonal changes, not disease.

This approach can save postmenopausal women from unnecessary colposcopies. If you are past menopause and receive an ASCUS result with a negative HPV test, it is worth asking your clinician whether a trial of vaginal estrogen before the next Pap might clarify things. The underlying risk profile is still low, but cleaning up the diagnostic picture can reduce both confusion and follow-up procedures.

When Immune Status Changes the Calculus

The reassuring data on HPV-negative ASCUS come primarily from studies of women with healthy immune systems. If you are immunocompromised, particularly if you are living with HIV, the management approach can differ. Guidelines for HIV-positive women have traditionally been more cautious with any abnormal Pap result. For women with HIV who receive an ASCUS result, some guidelines recommend either immediate colposcopy or a repeat Pap in six to twelve months, with colposcopy if the repeat still shows ASCUS or anything worse.⁷

The reason is that immunocompromised people clear HPV infections less reliably and can progress to precancer more quickly. They are also more likely to have false-negative HPV tests because their immune response to the virus behaves differently. If you take immunosuppressive medications for an organ transplant, an autoimmune condition, or another reason, talk to your clinician about whether the standard three-year return applies to you. In many cases, it does not.

Liquid-Based Cytology and Sample Quality

Not all Pap smears are created equal. The shift from conventional Pap smears (where cells are smeared directly onto a slide) to liquid-based cytology (where cells are rinsed into a preservative fluid) has improved the detection of abnormalities across the board, including ASCUS and higher-grade lesions.⁸ Liquid-based preparations reduce issues like obscuring blood or mucus and produce more evenly distributed cells, which makes the pathologist’s job easier.

This matters for ASCUS in a practical way. An ASCUS reading on a high-quality liquid-based sample is somewhat more meaningful than one on a mediocre conventional smear, where artifact and poor preservation could easily nudge borderline cells into the “atypical” category. Most labs in the United States now use liquid-based cytology, but if you are screened in a setting that still uses conventional smears, the chance that your ASCUS result is a technical artifact rather than a true cellular change is modestly higher. This does not change the management recommendation, but it does add context to why ASCUS exists as a category in the first place: it partly reflects the limits of any cytology method.

Newer Triage Tools on the Horizon

Researchers have been working on better ways to sort ASCUS results into those that need attention and those that do not, beyond just HPV testing. One promising approach is p16/Ki-67 dual-stain cytology, which looks for two proteins that cells express when they are being driven toward abnormal growth by HPV. In a European study of women with ASCUS, dual-stain cytology detected over 92 percent of underlying CIN2-or-worse lesions while correctly ruling out disease in about 81 percent of women without significant precancer. That specificity was higher than HPV testing alone.⁹

The appeal of dual staining is that it could reduce the number of women sent for colposcopy unnecessarily after an ASCUS result while still catching real precancer. It is gradually becoming available in clinical practice, though it has not yet replaced HPV triage as the standard first step. For HPV-negative ASCUS specifically, dual staining is unlikely to change the management much because the risk is already so low. But for HPV-positive ASCUS, where the next step currently involves colposcopy, dual staining could eventually help separate the women who truly need that procedure from those who could safely wait.

The Anxiety Problem

Even when the medical risk is low, the emotional experience of an abnormal Pap result can be intense. Research on women who receive borderline or equivocal screening results consistently finds elevated anxiety. In one study, nearly half of women with borderline Pap results reported high anxiety levels, and their mental quality of life scores were significantly worse than those of women with normal results.¹⁰ Over a quarter of the borderline-result group described screening as “frightening,” compared with about one in ten women with normal results.

A separate qualitative study found that most women were confused about what their abnormal screening results actually meant and that searching online made things worse, surfacing worst-case scenarios and generic information that did not resolve their specific questions.¹¹ This is worth naming directly: if you are reading this article because you just got an ASCUS result and you feel anxious, that reaction is completely normal and extremely common. The clinical reality, though, is that HPV-negative ASCUS is one of the most benign abnormal results you can receive. The three-year follow-up is not a gamble. It reflects years of outcome data on hundreds of thousands of women showing that the risk is genuinely small.

How HPV Testing Accuracy Varies With Age

One detail worth knowing is that the accuracy of HPV testing improves with age. A large European cohort study found that both Pap and HPV tests had higher specificity in women over 35 compared with younger women.¹² Younger women are more likely to carry transient HPV infections that clear on their own, which generates more positive HPV results that do not lead to disease. By contrast, a negative HPV result in a woman over 30 or 35 is an especially strong signal, because the test is less likely to be muddied by harmless passing infections.

This means the reassurance of a negative HPV test alongside an ASCUS result is actually somewhat stronger for women in their 30s, 40s, and beyond than for women in their early 20s. For women under 25, current U.S. guidelines do not even recommend HPV co-testing because transient infections are so common that the test creates more confusion than clarity. If you are over 30 and your HPV-negative ASCUS result came from a co-test, the data backing your three-year return interval is particularly robust.

Cost-Effectiveness of the Current Approach

The 2019 ASCCP guidelines were also evaluated for their economic impact. A modeling study found that managing screening results according to the 2019 risk-based framework was both less costly and more effective than the older 2012 guidelines, resulting in fewer colposcopies and fewer cancer deaths across all modeled scenarios.¹³ Fewer colposcopies is not just a cost-saving measure. Each avoided colposcopy means one fewer woman experiencing the discomfort, anxiety, and potential overtreatment that come with investigating a finding that was overwhelmingly likely to be benign. For HPV-negative ASCUS specifically, the risk-based approach confirms what the outcome data already showed: watchful waiting with a three-year return is the right balance between vigilance and restraint.

When to Push for Earlier Follow-Up

The standard three-year recommendation works well for most people, but a few situations justify asking your clinician about coming back sooner:

Prior treated precancer: If you have had a LEEP, cone biopsy, or similar treatment for CIN2 or CIN3 in the past, your baseline risk is higher than someone with no such history, and the standard low-risk timeline may not apply.
Immunosuppression: As discussed above, HIV or immunosuppressive medication changes the risk equation.
Persistent symptoms: Unexplained bleeding between periods, bleeding after intercourse, or unusual discharge warrant evaluation regardless of what any screening test says.
Repeated ASCUS results: If this is your second or third ASCUS in a row, even with negative HPV, the pattern itself is worth discussing with your clinician.

Outside of these scenarios, requesting an earlier repeat Pap “just to be safe” does not improve outcomes and can lead to unnecessary procedures. The guidelines exist precisely to prevent the cascade of testing and anxiety that follows low-risk results. Trusting the three-year timeline is, for the vast majority of women with HPV-negative ASCUS, the most evidence-based thing you can do.